Francisco José Zapatero Belinchón

This study identifies Mac1 as a therapeutic target for SARS-CoV-2 and demonstrates that AVI-4206, a small molecule inhibitor, reduces viral replication and improves survival in an animal model.

This paper develops RocASO, a molecular glue-oligonucleotide conjugate that selectively inhibits mRNA translation by targeting specific sequences, showing potent antiviral activity against SARS-CoV-2.

This paper describes the discovery of new coronavirus MPro inhibitors with improved pharmacokinetics, broad-spectrum antiviral activity, and superior in vivo efficacy compared to existing drugs.

This study identifies the L260F mutation in NSP6 as enhancing RNA replication and pathogenesis in recent SARS-CoV-2 variants, independent of Spike function.

This paper shows NRF2 activators inhibit coronaviruses by downregulating ACE2, TMPRSS2, and XPO1, independent of NRF2 signaling.